Axsome stock: buy or sell?
February 26th, 2020
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders.
Should I buy Axsome stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading strategy that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Axsome stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Axsome stock a buy?
Banks and financial institutions publish stock ratings everyday.Unfortunately, we couldn't detect any rating for AXSM stock for the last 30 days.
Axsome stock analysis
Shares of Axsome decreased a bad -1.11% and closed at $83.82.
Axsome Therapeutics closed today at $83.82 and decreased a bad -1.11%. Since price and SMA200d lines crossed up on October, AXSM climbed $65.58 (359.54%). Since SMA50d and SMA100d crossed up on December, AXSM price climbed $38.21 per share (83.78%). On December, AXSM hit new all time highs, pushing higher previous ATH of $107.87 recorded on December. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
After climbing for 4 weeks, this week Axsome collapsed a bloodcurdling -8.02%, closing at $83.82.
Axsome Therapeutics stock just marked a top under its last top. Athought it's not something to really worring right now, investors in AXSM should be alerted as this could be a warning for future complications. You should be expectant to Axsome Therapeutics price to not slide under , as this would complicate possible price recovery in the short and mid-term. Not so far away is the last price record Axsome marked late December 2019, but since then it dropped a 23.76%. Since mid October 2019 when AXSM stock price broke up the SMA40w line, it gained $65.68 (362.07%). Early December, SMA10w and SMA20w crossed up triggering a rise of 112.90%.
Axsome stock price history
Axsome IPO was on November 19th, 2015 at $9.00 per share1. Since then, AXSM stock grew a 831.30%, with a yearly average of 207.80%. If you had invested right after AXSM's IPO a $1,000 in Axsome stock in 2015, it would worth $8,313.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Axsome stock historical price chart
AXSM stock reached all-time highs on December with a price of $109.94.
Axsome stock price targetPredicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not detected any price target for Axsome stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Axsome was in line with the forecasts of the analysts and posted an EPS of $-0.32 per share. Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn , Axsome Therapeutics annual revenues to M dollars from marked in . , its profit margin (compared to revenues) to , that is million.
Quarterly financial resultsReported quarter income marked $-9.60 million with a profit margin of . Profit margin remained steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Axsome Therapeutics sales marked a neutral move and stayed constant a nan%. Looking back to recent quarterly results, Axsome posted 7 positive quarters in a row.
Axsome ownershipWhen you are planning to invest in shares of a stock, it's always worth to check its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Axsome, 22.30% of all outstanding shares are owned by its staff.
In case of Axsome Therapeutics stock, 61.29% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AXSM stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related companies:
|Market cap||$3.1 B|
|Total shares||37.0 M|
|Float shares||24.6 M|
|- Institutional holdings (%)||61.3%|
|- Insider holdings (%)||22.3%|
|Shares in short selling||0.0%|
|Wednesday, February 26th, 2020|
|Day range||$82.23 - $86.81|
|Average true range||$4.34|
|50d mov avg||$90.92|
|100d mov avg||$59.86|
|200d mov avg||$42.30|
Axsome performanceTo better understand Axsome Therapeutics performance you must compare its gains with other related stocks in same sector or industry. For Axsome, the comparison is made against .